1. Home
  2. REVB vs VRAX Comparison

REVB vs VRAX Comparison

Compare REVB & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • VRAX
  • Stock Information
  • Founded
  • REVB 2020
  • VRAX 2013
  • Country
  • REVB United States
  • VRAX United Kingdom
  • Employees
  • REVB N/A
  • VRAX N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • REVB Health Care
  • VRAX Health Care
  • Exchange
  • REVB Nasdaq
  • VRAX Nasdaq
  • Market Cap
  • REVB 3.4M
  • VRAX 2.8M
  • IPO Year
  • REVB N/A
  • VRAX 2022
  • Fundamental
  • Price
  • REVB $1.35
  • VRAX $0.59
  • Analyst Decision
  • REVB
  • VRAX Strong Buy
  • Analyst Count
  • REVB 0
  • VRAX 1
  • Target Price
  • REVB N/A
  • VRAX $3.00
  • AVG Volume (30 Days)
  • REVB 195.9K
  • VRAX 173.2K
  • Earning Date
  • REVB 11-07-2025
  • VRAX 01-01-0001
  • Dividend Yield
  • REVB N/A
  • VRAX N/A
  • EPS Growth
  • REVB N/A
  • VRAX N/A
  • EPS
  • REVB N/A
  • VRAX N/A
  • Revenue
  • REVB N/A
  • VRAX $6,331.00
  • Revenue This Year
  • REVB N/A
  • VRAX $217,274.83
  • Revenue Next Year
  • REVB N/A
  • VRAX N/A
  • P/E Ratio
  • REVB N/A
  • VRAX N/A
  • Revenue Growth
  • REVB N/A
  • VRAX N/A
  • 52 Week Low
  • REVB $1.15
  • VRAX $0.52
  • 52 Week High
  • REVB $60.48
  • VRAX $3.20
  • Technical
  • Relative Strength Index (RSI)
  • REVB 42.07
  • VRAX 40.61
  • Support Level
  • REVB $1.23
  • VRAX $0.60
  • Resistance Level
  • REVB $1.38
  • VRAX $0.62
  • Average True Range (ATR)
  • REVB 0.08
  • VRAX 0.03
  • MACD
  • REVB 0.03
  • VRAX -0.00
  • Stochastic Oscillator
  • REVB 57.65
  • VRAX 8.50

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

Share on Social Networks: